Lavinia Cristina Pădurariu, Octavian Marius Dincă, George Cristian Vlădan, Tiberiu Niță, Alexandru Bucur

Abstract

Medication related osteonecrosis of the jaw is a heterogeneous clinical entity with common pathology features and their diagnosis and management remains a dilemma for many clinicians. During the current SARS-CoV-2 virus pandemic, an extensive therapeutic arsenal is being used that includes traditional immunosuppressive and repurposed drugs, so it is important to understand their possible adverse effects. We describe the diagnosis, clinical course, and management of a 65-year-old female patient undergoing previously intravenous bisphosphonates (BPs) therapy and recently was treated with corticosteroid for the prevention of multi-inflammatory syndrome during the course of COVID-19. In this context, possible pathophysiological links between osteonecrosis of the jaw and medication used to treat non-severe COVID-19 infection are discussed. It should be underlined that osteonecrosis of the jaw unrelated to BPs may be a rare complication associated with concomitant corticotherapy. This case highlights the need for rapid dissemination of clinical information related to the multidisciplinary care of patients with COVID-19 who were managed by corticosteroids.